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Abstract In porcine coronary arteries, short-term treatment
with resveratrol (RSVL) substantially inhibited MAPK activity
(IC50 = 37 WM); and immunoblot analyses revealed consistent
reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38,
at active sites. Endothelin-1 (ET-1), a primary antecedent in
coronary heart diseases, enhanced MAPK activity, phosphoryla-
tion and nuclear translocation in a concentration-responsive but
RSVL-sensitive manner. RSVL had no effect on basal or
forskolin-stimulated cAMP levels, a known downregulator of
the MAPK cascade. Likewise, inhibition of MAPK by RSVL
was not reversed by the estrogen receptor blockers tamoxifen and
ICI-182,780. Conversely, RSVL remarkably attenuated basal
and ET-1-evoked protein tyrosine phosphorylation. Because
MAPKs promote smooth muscle proliferation and contraction,
their current inhibition may contribute to the putative protection
by RSVL against coronary heart diseases. These effects
apparently do not involve interaction with estrogen receptors.
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1. Introduction
Evidence from epidemiological and experimental studies
that natural edible compounds can protect against diseases
is currently best exempli¢ed by resveratrol [1]. Resveratrol
(RSVL), a phytoalexin in grapes, berries and peanuts, has
been shown to interfere with tumor initiation, promotion
and progression in di¡erent systems [2,3]. At the molecular
level, these e¡ects were related to inhibition of ribonucleotide
reductase with cellular arrest in the S-phase or the S/G2 phase
transition [4,5]. Likewise, stimulation of adenylyl cyclase and
inhibition of hydroperoxidase or cyclooxygenase have been
reported in various systems [2,6].
In contrast to other systems, little is known about the cel-
lular/molecular mechanisms whereby RSVL could protect
against coronary heart diseases [1]. Resveratrol and related
stilbenes such as quercetin relaxed rat aortic rings through
an endothelium-mediated enhancement of the NO-cGMP cas-
cade [7]. Subsequent pharmacological studies indicated a di-
rect relaxant component exerted on vascular smooth muscle,
though of unknown nature [8]. Indeed, whether resveratrol’s
antiproliferative e¡ects could be mimicked in smooth muscles
remains an intriguing possibility.
Among the endogenous mediators of cardiovascular disor-
ders, endothelin-1 (ET-1), a 21 amino acid peptide, is a pri-
mary antecedent in coronary heart diseases [9^12]. Such ef-
fects are mediated by extremely potent vasopressor, and
mitogenic responses for ET-1 in the vasculature [10,11]. Re-
sults from preclinical studies on humans, as well as from
studies on animals, showed that plasma ET-1 levels are con-
sistently elevated in many spasm-related cardiovascular dis-
eases [11,13], and that blockers for ET receptors can substan-
tially alleviate complications of such diseases [13,14]. In
eliciting its biological responses, ET-1 targets a variety of
molecular e¡ectors including activation of mitogen-activated
protein kinases (MAPKs), a superfamily of proline-directed
serine/threonine protein kinases [15]. MAPKs, in addition to
growth factors, are also upregulated with environmental stress
signals such as heat shock, irradiation, osmotic stress and
ischemia [16]. This superfamily of enzymes includes the ex-
tracellular signal-regulated kinases (ERKs) and the stress-ac-
tivated protein kinases (SAPKs). The latter subfamily encom-
passes c-Jun N-terminal kinases (JNKs) and p38 MAP kinases
[16^18]. Downstream targets for the action of MAPKs com-
prise mitogenic/proin£ammatory enzymes and nuclear tran-
scription factors [19,20]. Moreover, multiple evidence now
suggests a positive impact for MAPK on mechanisms culmi-
nating in smooth muscle contraction [21,22].
The present study was undertaken to identify potential sig-
naling components underlying resveratrol’s protective actions
in coronary artery. Because of endothelin’s pathophysiological
in£uence on the cardiovascular system, we investigated the
capacity of this peptide to activate the MAPK pathways,
ERK-1/-2, JNK-1 and p38, and to upregulate tyrosine kinase
activity in coronary artery. Further, we examined whether
RSVL can inhibit these enzymes in the presence and absence
of ET-1. To our knowledge, this is the ¢rst report to demon-
strate downregulation of MAPK/JNK/p38 by RSVL in the
vasculature, a plausible mechanism that could account, at
least in part, for its cardiovascular bene¢ts.
2. Materials and methods
2.1. Materials
The MAPK peptide substrate (APRTGGRR) was purchased from
Calbiochem. ET-1 was obtained from Phoenix Pharmaceuticals. P-81
phosphocellulose paper discs were from Gibco. cAMP enzyme immu-
noassay kit was from Biomol. The anti-MAPK, anti-P-ERK-1/-2,
anti-P-JNK-1, anti-P-p38 anti-phosphotyrosine (PY-99), the horserad-
ish peroxidase-linked secondary antibodies and protein agarose A
were from Santa Cruz. Anti-histone H1 was from Upstate Biotech-
nology. ICI-182,780 was from Tocris, and tamoxifen was from Cal-
biochem. Various proteinase and phosphatase inhibitors were ob-
tained from Sigma Chemical Co.
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2.2. Subcellular fractionation
Left anterior descending coronary arteries of pig hearts were dis-
sected out and their endothelia were mechanically removed. Following
equilibration and initial RSVL/ET-1 treatments, subcellular nuclear
fraction was prepared according to the method of Mizukami et al.
[23]. Thus, arterial smooth muscle layers were isolated on ice and then
homogenized using a Polytron homogenizer in 2 volumes of STE
bu¡er (0.32 M sucrose, 10 mM Tris-HCl, pH 7.4, 1 mM EGTA,
2 mM EDTA, 5 mM NaN3, 10 mM L-mercaptoethanol, 20 WM leu-
peptin, 0.2 mM phenylmethylsulfonyl £uoride, 50 mM NaF, 1 mM
sodium orthovanadate and 50 mM L-glycerophosphate). The homo-
genates were mixed with two volumes of STE bu¡er and centrifuged
(1000Ug, 10 min, 4‡C). The pellet (nuclear fraction) was washed once
by suspension in STE and centrifugation then solubilized in Triton
bu¡er (1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4,
1 mM EGTA, 1 mM EDTA, 20 WM leupeptin, 0.2 mM phenyl-
methylsulfonyl £uoride, 50 mM NaF, 0.2 mM sodium orthovanadate
and 30 mM L-glycerophosphate). This nuclear extract was centrifuged
(15000Ug, 30 min, 4‡C) and the supernatant was separated, aliquoted
and stored at 380‡C.
2.3. Determination of MAPK activity
Arteries, prepared as outlined above, were cut into strips to satisfy
the needs of di¡erent treatments, and equilibrated in Krebs-Ringer
bicarbonate bu¡er at 37‡C for 60 min with the bu¡er replaced with
fresh one at 20 min intervals. Muscle strips were treated with RSVL
(20 min) and/or ET-1 (5 min) versus control from the same tissues.
Reactions were terminated by ice cooling. Smooth muscle strips were
¢nely chopped on ice and suspended in 4 volumes ice-cold homoge-
nization bu¡er (Tris-HCl, pH 7.4, 20 mM; dithiothreitol, 1 mM;
EGTA, 1 mM; EDTA, 1 mM; phenylmethylsulfonyl £uoride,
1 mM; leupeptin, 10 Wg/ml; aprotinin, 2 Wg/ml and Triton X-100,
0.1%. After homogenization with a Polytron homogenizer, the homo-
genate was centrifuged at 13 000Ug (4‡C). Protein concentration of
extracts was determined by the method of Lowry et al. [24]. MAPK
was immunoprecipitated by treatment with mammalian anti-ERK
antibody (1:500) for 2 h (4‡C), as determined by preliminary experi-
ments. Protein agarose A (20 Wl/ml) was then added with rocking for
2 h (4‡C) and the immune complexes were pelletted by centrifugation
at 2500 rpm for 5 min (4‡C). Pellets were washed three times, by
suspension and centrifugation, in homogenization bu¡er and once
in assay bu¡er (Tris-HCl, 50 mM (pH 7.5); MgCl2, 10 mM; L-gly-
cerophosphate, 50 mM; sodium pyrophosphate, 1 mM; and sodium
vanadate, 0.1 mM). ERK activity was determined in a total volume of
25 Wl that contained V30 Wg protein equivalent of immune complex,
5 Wg of the speci¢c MAPK substrate APRTPGGRR and 100 WM cold
ATP/1.0 WCi [Q-32P]ATP (4 mCi/Wmol). Reactions were carried out at
30‡C for 30 min, and were terminated by spotting (12 Wl) onto p-81-
phosphocellulose paper discs; which bind the phosphorylated sub-
strate by ion-exchange chromatography. Discs were then washed
(2U10 min) with 1% phosphoric acid and (2U5 min) with distilled
water. The 32P incorporation into the MAPK substrate was deter-
mined by liquid scintillation counting.
2.4. Determination of cAMP
Smooth muscle strips were equilibrated in Krebs-Ringer bicarbon-
ate bu¡er at 37‡C for 60 min with the bu¡er replaced with fresh one
at 20 min intervals. 3-Isobutyl-1-methylxanthine (IBMX; 0.1 mM)
was then added for 15 min prior to treatment with RSVL, forskolin
or their combination (20 min). cAMP was extracted by 0.1 M HCl,
determined by enzyme immunoassay and its levels were normalized to
smooth muscle wet weight.
2.5. Immunoblot analysis
Arterial strips were treated with RSVL (20 min) and/or ET-1 (5 min)
versus control. The estrogen receptor blockers tamoxifen or ICI-
182,780 were added 15 min before RSVL treatment. Smooth muscle
lysates were prepared as described above using the ice-cold homoge-
nization bu¡er (Tris-HCl, pH 7.4, 20 mM; dithiothreitol, 1 mM;
EGTA, 1 mM; EDTA, 1 mM; phenylmethylsulphonyl £uoride,
1 mM; leupeptin, 10 Wg/ml; aprotinin, 2 Wg/ml; Triton X-100, 1%;
NP-40, 1%; sodium deoxycholate, 0.5%) and the phosphatase inhib-
itors, L-glycerophosphate (50 mM), sodium pyrophosphate (1 mM)
and sodium vanadate (1 mM). The 13 000Ug supernatant was-
isolated, aliquoted and stored at 380‡C. Protein content of the cel-
lular or nuclear lysates was determined by the method of Lowry et al.
Samples (30^60 Wg) were separated by discontinuous SDS-PAGE on a
10^12% gel, according to the method of Laemmli [25], and proteins
were electrotransferred to PVDF membranes. Membranes were rever-
sibly stained with Ponceau-S red to ensure the homogeneity of protein
blotting. Membrane proteins were then probed with primary antibod-
ies, as follows: a rabbit anti-ERK (1:3000) in 5% non-fat dry milk,
mouse anti-P-ERK1/ERK2 (1:2000), mouse anti-P-JNK (1:2000),
mouse anti-P-p38 (1:2000) in 2% BSA or mouse anti-phosphotyrosine
antibody (PY-99, 1:3000) in 4% BSA. Primary antibodies were then
detected with appropriate secondary antibodies linked to horseradish
peroxidase (1:2000^1:3000) and signals were visualized by the en-
hanced chemiluminescence system using a kit from New England
Biolabs.
2.6. Statistical analysis
All data are expressed as mean þ S.E.M. Comparisons between two
groups were made by Student’s t-test and among multiple groups by
the one-way ANOVA test. A probability less than 0.05 was consid-
ered to indicate a signi¢cant di¡erence.
3. Results
3.1. Inhibition of MAPK activity, phosphorylation and nuclear
translocation
Treatment of coronary arteries with resveratrol for 20 min,
as guided by preliminary studies, inhibited MAPK activity in
a concentration-dependent fashion (IC50 37 þ 4.2 WM) (Fig.
1A). Western blotting under similar experimental conditions,
with antibodies against the phosphorylated (activated) ERK-
1/-2 (anti-P-ERKs) or against protein tyrosyl phosphate (PY-
99), revealed considerable reductions in the phosphorylation
of p-44 and p-42 bands (MAPK isoforms), implying that
RSVL possibly interferes with the mechanisms underlying
MAPK activation (Fig. 1A). ET-1, as an extracellular activa-
tor, increased MAPK activity by 2^3-fold in a concentration-
responsive manner. Pretreatment with RSVL (50 WM) attenu-
ated ET-1-enhanced MAPK activity (Fig. 1B). As can be seen
in Fig. 2, modulation of ERK-1/-2 phosphorylation seems to
be the target for actions of both ET-1 and RSVL. Probing
total ERK protein levels with anti-ERK antibody, as indi-
cated by densitometry, showed no di¡erence in the total
amount of enzyme present among di¡erent treatments. To
further determine whether these mechanisms are operational
for cognate MAPK family members, such as JNK-1 and p38,
antibodies against the active (phosphorylated) forms of these
enzymes were employed. Fig. 2 indicates that ET-1 augmented
the phosphorylation of JNK-1 (p-46) and p38-MAPK, where-
as RSVL counteracted such e¡ects.
In addition to cytosolic targets, MAPK translocates to the
nucleus where it phosphorylates transcription factors. There-
fore, it was of interest to monitor levels of ‘P-ERK’ in the
nucleus and the e¡ects of ET-1 and/or RSVL thereon. To this
end, we prepared a nuclear subcellular fraction from coronary
arteries. Purity of this fraction was veri¢ed by immunodetec-
tion/densitometry of the nuclear marker protein (histone H1).
Histone H1 also served as an internal reference for protein
homogeneity among groups. Results indicated that histone H1
chie£y existed (V88^91%) in the nuclear ^ rather than in the
postnuclear ^ fraction (Fig. 3). Results in Fig. 3 demonstrate
that P-ERK translocation to the nucleus is appreciably en-
hanced by ET-1, a response that was markedly reduced by
RSVL.
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3.2. E¡ect on cAMP/protein kinase A (PKA)
The cAMP/PKA system, a known inhibitor of the MAPK
cascade, is upregulated by RSVL in polymorphonuclear
(PMN) leukocytes. However, similar stimulation by RSVL
in vasculature has not been demonstrated. Measurements of
cAMP levels (Fig. 4A) suggested that RSVL (10^1000 WM)
had no e¡ect on adenylyl cyclase (AC) activity in coronary
smooth muscle. Similar results were obtained when the phos-
phodiesterase inhibitor, IBMX, was omitted from incuba-
tions, when AC was stimulated with forskolin or isoproterenol
or when PKA activity was measured in the presence of RSVL
(data not shown).
Previous studies have suggested a potential action of RSVL
on receptors for estradiol (E2), a known activator of AC and
inhibitor of MAPKs in vascular smooth muscle [1]. Therefore,
it was of concern to determine whether RSVL-induced inhib-
ition of MAPK activity involved activation of E2 receptor. As
illustrated in Fig. 4B, pretreatment with blockers for E2 re-
ceptor, tamoxifen or ICI-182,780 (1 WM), did not reverse the
inhibition of ERK-1/-2 phosphorylation by RSVL.
3.3. Inhibition of cellular protein tyrosine phosphorylation
Tyrosine phosphorylation is an established upstream pro-
moter of MAPK activity. Because RSVL is a polyphenolic
compound, we considered that it could potentially a¡ect pro-
tein tyrosine phosphorylation. Fig. 5 shows that RSVL sup-
pressed basal as well as ET-1-evoked protein tyrosine phos-
phorylation.
4. Discussion
The putative cardiovascular bene¢ts of RSVL have been
related to inhibition of platelet aggregation, perturbation of
prostanoid synthesis and regulation of lipoprotein metabolism
[26] ; however, the cellular and molecular targets of RSVL
action remained largely ambiguous. We currently demonstrate
Fig. 2. ET-1 (0.1 WM)-induced phosphorylation of ERKs, JNK-1
and p38 and the e¡ect of RSVL (50 WM) thereon; a representative
of three similar experiments.
Fig. 3. Western blotting for detection of P-ERK-1/-2 levels relative
to the total enzymes (ERK-1/-2) in a nuclear subcellular fraction in
response to ET-1 and/or RSVL treatments. Densities of the nuclear
marker histone H1 in nuclear and postnuclear fractions are also
shown; a representative of three similar experiments.
Fig. 1. RSVL inhibits MAPK activity in porcine coronary arteries in a concentration-responsive manner (A, n = 4); inset shows corresponding
phosphorylation levels of MAPK as determined by Western blotting from similar treatments (a representative of three similar blots). B: Rever-
sal of ET-1-induced MAPK activation by resveratrol (50 WM). *Signi¢cantly di¡erent from control and #signi¢cantly di¡erent from ET-1 alone
(n = 4^5).
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the upregulation/nuclear translocation of MAPK family of
enzymes by ET-1 and their inhibition by RSVL in coronary
arteries even in the absence of ET-1. These e¡ects for RSVL
involved hypophosphorylation of MAPKs at active sites. The
IC50 value found for MAPK inhibition (37 WM) was compar-
able to those reported for inhibition of other enzymes such as
hydroperoxidase, cyclooxygenase and ribonucleotide reduc-
tase (15^100 WM) in various systems [2,4].
Given its chemical structure and biological pro¢les in E2-
responsive systems, RSVL was considered a phytoestrogen [1].
Although RSVL was shown to be a ‘superagonist’ in the E2
receptor-dependent breast cancer cells MCF-7 [27], it elicited
E2 receptor-independent e¡ects in cognate cell lines [3]. In the
vasculature, E2 is known to lower the incidence of cardiovas-
cular diseases among premenopausal women [28,29]. In light
of similar protective e¡ects, RSVL was speculated to be an
‘estrogen agonist’ in the vasculature [1]. The E2-evoked vaso-
dilatory and antiproliferative e¡ects in vascular smooth
muscles involve activation of AC and the nitric oxide/cGMP
systems, as well as inhibition of MAPK signal [28^31]. On the
other hand, in rat aorta, RSVL augmented NO and cGMP
production evidently via an endothelium-dependent mecha-
nism [7,8], and stimulated cAMP formation in PMN leuko-
cytes [6]. Because stimulation of the cAMP/PKA pathway
inhibits the MAPK cascade [32,33], we investigated the e¡ects
of RSVL on cAMP formation/PKA activity in coronary ar-
tery. Our data indicated that RSVL had no e¡ect on this
cascade. Moreover, RSVL-induced inhibition of MAPK phos-
phorylation was insensitive to the E2 receptor blockers tamox-
ifen and ICI-182,780l, thereby arguing against a role for estro-
gen receptors. However, exclusion of ‘estrogen-like’ e¡ects in
our system may be premature in light of recent reports sug-
gesting ‘direct’ receptor-independent responses for estradiol
[34]. In support, recent studies in E2-responsive pituitary tu-
mor cell lines demonstrated the inability of RSVL to bind E2
receptors, although it mimicked some of the E2 responses in
this system [35]. Clearly, RSVL is not merely an ‘E2-like com-
pound’, but exhibits unique pharmacological characteristics.
The cGMP/PKG system is another MAPK downregulator
in vascular smooth muscle [36]. Because RSVL’s agonistic
e¡ects on cGMP are both NO- and endothelium-dependent
[7,8], this mechanism may not be operational in our endothe-
lium-denuded arteries. Further, in such endothelium-free ar-
teries, the observed inhibition of MAPKs by RSVL may sub-
stantiate its vascular bene¢ts in diseases associated with
damaged endothelium such as atherosclerosis [37] or condi-
tions associated with elevated plasma levels of ET-1 and/or
growth factors [38].
Signal triggers mediating the spasmogenic/mitogenic e¡ects
of ET-1 in vasculature include activation of PLC, PKC, non-
receptor protein tyrosine kinases (n-PTK) and the MAPK
superfamily of enzymes [15,39]. Causal relationships in the
activation of these signals have also been established [40].
Not surprisingly, therefore, we found that the speci¢c MEK/
MAPK inhibitor, PD-98059, signi¢cantly attenuated ET-1-in-
duced contraction of porcine coronary artery (data not
shown), which is consistent with previous reports [21,22]. Ty-
rosine phosphorylation enhances ‘ras’ association with ‘c-raf-
1’ and is also an essential mechanism in the activation of
MAPK by MEK [36]. Moreover, PTKs are known to activate
Fig. 4. E¡ect of RSVL (10^1000 WM) on cAMP levels in porcine coronary artery (A, n = 4^6), and on ERK-1/-2 phosphorylation in the pres-
ence and absence of the estrogen receptor blockers, tamoxifen (TAM) or ICI-182,780, 1 WM each (B; a representative of three similar blots).
Fig. 5. Promotion by ET-1 (0.1 WM), but inhibition by RSVL (50
WM), of cellular protein tyrosine phosphorylation; a representative
of three similar blots.
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mitogenic and spasmogenic signals in smooth muscles [41,42].
The polyphenolic nature of RSVL motivated the initial ¢nd-
ing that it inhibits the activity of puri¢ed PTKs [43]. Because
we had shown previously that ET-1 activates n-PTKs in cor-
onary smooth muscle [12], it was reasonable to challenge
RSVL in such an ‘upregulated’ system. The present inhibition
of cellular tyrosine phosphorylation by RSVL is likely to con-
tribute to the downstream e¡ects on MAPKs.
Although RSVL is an edible compound, detailed pharma-
cokinetic information concerning its therapeutic bene¢ts has
been lacking. A recent elegant ‘population study’ now pro-
vides evidence that beverage intake of RSVL results in su⁄-
cient absorption/plasma levels to account for its bene¢cial
health e¡ects [44]. Collectively, the present study suggests
the MAPK and PTK pathways are important ‘targets’ for
the pathophysiological impact of ET-1 in the etiology of cor-
onary heart diseases as well as for the putative cardiovascular
protective e¡ects of RSVL. Inhibition of these enzymes could
help minimize the risk of smooth muscle cell proliferation and
spasm underlying coronary stenosis.
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